Travere Therapeutics Inc. (Nasdaq: TVTX) priced an upsized $475 million convertible senior notes offering due 2032, using the proceeds to refinance a portion of its nearer-term debt and fund general corporate purposes.
"Travere intends to use approximately $350.9 million of the net proceeds from the offering to repurchase approximately $221.4 million aggregate principal amount of its outstanding 2.25% senior convertible notes due 2029," the company said in a statement on May 7.
The offering was increased from an initial $400 million, with the new 0.50% notes carrying an initial conversion price of approximately $64.90 per share. The company expects net proceeds of about $460 million, which could rise to $508.5 million if underwriters led by J.P. Morgan, Jefferies, and Leerink Partners exercise their full over-allotment option.
The transaction allows Travere to push out its debt maturity to 2032 from 2029 while locking in a lower coupon rate. However, the conversion feature introduces potential share dilution for existing stockholders if the stock price rises significantly above the $64.90 conversion price before maturity.
The sale of the notes is expected to close on May 11, 2026. The notes will be senior unsecured obligations and will be convertible by holders only after certain conditions are met before February 17, 2032. After that date, holders can convert at any time until the maturity date. Upon conversion, Travere may settle in cash, common stock, or a combination of both.
The company also noted that if a "make-whole fundamental change" such as a merger occurs, it will, in certain circumstances, increase the conversion rate for a specified period. Travere may redeem the notes on or after May 21, 2029, but only if its stock price exceeds 130% of the conversion price for a specified period.
Concurrently with the offering, Travere entered into privately negotiated transactions to repurchase the 2029 notes. The company expects that holders of the repurchased notes who had hedged their positions will unwind those hedges by buying Travere's common stock, which could increase the stock's trading volume and price.
This article is for informational purposes only and does not constitute investment advice.
